Abstract:8544Background: Circulating tumor DNA (ctDNA) is a noninvasive assessment that can be used as an alternative method to detect gene mutations in lung cancer patients. However, previous studies have analyzed only a small subset of genes like EGFR and KRAS using a variety of detection methods. Feasibility to evaluate concordance between tumor tissue DNA(tDNA) and plasma ctDNA mutations in a large number of genes need to be assessed. We used a relatively inexpensive targeted sequencing method to analyze and compare mutations between tumor tissue and plasma. Methods: Fresh tumor tissue, peripheral blood lymphocytes and plasma samples were collected prospectively from 167 non-small-cell lung cancer(NSCLC) patients before treatment. We utilized the Ion PGM and AmpliSeq Cancer Panel which covers 739 mutational hotspot loci in 50 oncogenes and tumor suppressor genes in matched tDNA and plasma ctDNA samples with matched white blood cell DNA as a control. Results: Of the 167 NSCLC sample pairs analyzed, 118 containe...

Comparison Between Circulating Tumor Dna And Tumor Tissue Multiple Gene Detection In Non-Small Cell Lung Cancer Patients By Targeted Sequencing With The Ion Pgm And Ampliseq Cancer Panel.